Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Colomb. med ; 49(3): 244-248, July-Sept. 2018. graf
Article in English | LILACS | ID: biblio-974993

ABSTRACT

Abstract Introduction: Primary stabbing headache (or "ice pick headache") is an alteration characterized by brief jabs (short stabs of pain, lasting ~3 seconds), which appear spontaneously, irregularly, and affecting unilaterally or bilaterally. Indomethacin has traditionally been used as the main therapeutic option. However, this drug is ineffective in a considerable percentage of patients and can generate multiple adverse effects that occur at therapeutic doses. Clinical case: A 7-year-old male patient with primary stabbing headache of mild to moderate intensity, lasting 3 to 4 seconds, without relevant history, with normal neurodevelopment, neurological examination and neuroimaging; no triggers were identified. It was started therapeutic trial with Coenzyme Q10; however, no improvement in the symptoms was identified. Treatment and outcomes: A therapeutic management was carried out with Melatonin, which led to complete remission of the symptoms; without adverse effects in the posterior follow-up months. Clinical and scientific relevance: There is little information regarding effective and safe treatments for primary stabbing headache in children. The present case identifies Melatonin as an innovative, effective and safe therapeutic alternative in the treatment of primary stabbing headache in children. This is a significant advance in the understanding of primary stabbing headache in the pediatric population. Conclusion: Melatonin may be an effective and safe therapeutic option for the treatment of primary stabbing headache in pediatric patients. It is necessary to deepen its research, in order to establish its use in a clinical practice guide.


Resumen Introducción: La cefalea punzante primaria, es una alteración que se caracteriza por punzadas breves (∼3 segundos), que aparecen espontáneamente, de forma irregular y afectación unilateral o bilateral. Tradicionalmente se ha utilizado Indometacina como opción terapéutica principal. Sin embargo, este medicamento es inefectivo en un porcentaje considerable de pacientes y puede generar múltiples efectos adversos que se presentan a dosis terapéuticas. Caso clínico: Paciente masculino de 7 años de edad con cefalea punzante primaria de intensidad leve a moderada con una duración entre 3 y 4 segundos sin antecedentes relevantes, con neurodesarrollo, examen neurológico y de neuroimagen normales; no se identificaron desencadenantes. Se inició prueba terapéutica con Coenzima Q10, sin embargo no se identificó mejoría en los síntomas. Tratamiento y resultados: Se realizó un manejo terapéutico con Melatonina que conllevó a remisión completa de la sintomatología y sin efectos adversos en los meses posteriores de seguimiento. Relevancia clínica y científica: Existe poca información respecto a tratamientos efectivos y seguros para cefalea punzante primaria en niños. El presente caso identifica la Melatonina como una alternativa terapéutica innovadora, efectiva y segura en el tratamiento de la cefalea punzante primaria en niños. Lo anterior constituye un avance significativo en la comprensión de la cefalea punzante primaria en la población pediátrica. Conclusión: La melatonina puede ser una opción terapéutica efectiva y segura para el tratamiento de la cefalea punzante primaria en pacientes pediátricos. Se requiere ahondar en su investigación para establecer su uso en una guía de práctica clínica.


Subject(s)
Child , Humans , Male , Headache Disorders, Primary/prevention & control , Melatonin/therapeutic use , Antioxidants/therapeutic use , Follow-Up Studies , Ubiquinone/analogs & derivatives , Ubiquinone/therapeutic use , Treatment Outcome , Headache Disorders, Primary/drug therapy , Melatonin/adverse effects , Antioxidants/adverse effects
2.
Arq. bras. oftalmol ; 81(3): 226-231, May-June 2018. tab, graf
Article in English | LILACS | ID: biblio-950449

ABSTRACT

ABSTRACT Purpose: Nitrogen mustard (NM) is a devastating casualty agent in chemical warfare. There is no effective antidote to treat NM-induced ocular injury. We aimed to assess the effects of proanthocyanidin (PAC) and coenzyme Q10 (CoQ10) on NM-induced ocular injury. Methods: Eighteen male rats were divided into the following 4 groups: NM, NM + PAC, NM + CoQ10, and control. The 3 NM groups received a single dose of NM (0.02 mg/μL) on the right eye to induce ocular injury. The control group received saline only. Thirty minutes after the application of NM, the NM + PAC group received PAC (100 mg/kg) via gastric gavage, while the NM + CoQ10 group received CoQ10 (10 mg/kg) via intraperitoneal injection. PAC and CoQ10 were administered once a day for 5 consecutive days. The rats were then sacrificed. Macroscopic images of the eyes were examined and eye tissues were collected for histology. Results: The treatment groups were compared to the control group with regard to both corneal opacity and lid injury scores. The findings were not significantly different for both the NM + PAC and NM + CoQ10 groups. In both the NM + PAC and NM + CoQ10 groups, the histological changes seen in the NM group demonstrated improvement. Conclusions: Our results indicate that PAC and CoQ10 treatments have therapeutic effects on NM-induced ocular injury in a rat model. PAC and CoQ10 may be novel options in patients with NM-induced ocular injury.


RESUMO Objetivo: A mostarda de nitrogênio (MN) é um agente de guerra química devastador. Não existe um antídoto eficaz para tratar lesões oculares induzidas por MN. Nosso objetivo foi avaliar os efeitos da proantocianidina (PAC) e da coenzima Q10 (CoQ10) na lesão ocular induzida por MN. Métodos: Dezoito ratos machos foram divididos em 4 grupos: MN, MN + PAC, MN + CoQ10 e Controle. Três grupos receberam uma dose única de MN (0,02 mg/μL) destilada no olho direito para gerar lesão ocular. Os animais do grupo controle receberam apenas solução salina. Trinta minutos após a aplicação de MN nos animais, o grupo MN + PAC recebeu PAC (100 mg/kg) por gavagem gástrica, enquanto a CoQ10 (10 mg/kg) foi administrada ao grupo MN + CoQ10 por meio de injeção intraperitoneal. A administração de PAC e de CoQ10 foi realizada uma vez por dia, durante 5 dias consecutivos. Os ratos foram, então, sacrificados. Imagens macroscópicas dos olhos foram examinadas e tecidos oculares foram coletados para histologia. Resultados: Os grupos de tratamento foram comparados ao grupo de controle quanto à opacidade da córnea e quanto aos escores de lesão da cobertura da córnea. Os resultados foram insignificantes para ambos os grupos. Ambos, o grupo MN+PAC e o grupo MN+CoQ10, apresentaram melhoras das alterações histológicas observadas no grupo MN. Conclusões: Nossos resultados indicam que os tratamentos com PAC e com CoQ10 têm efeitos terapêuticos sobre lesões oculares induzidas por MN em um modelo em ratos. A proantocianidina e a CoQ10 podem ser uma nova opção nesses casos.


Subject(s)
Animals , Male , Rats , Burns, Chemical/drug therapy , Eye Injuries/drug therapy , Ubiquinone/analogs & derivatives , Proanthocyanidins/therapeutic use , Antioxidants/therapeutic use , Random Allocation , Chemical Warfare Agents , Eye Injuries/chemically induced , Ubiquinone/therapeutic use , Rats, Sprague-Dawley , Disease Models, Animal , Mechlorethamine
3.
Braz. j. otorhinolaryngol. (Impr.) ; 79(3): 293-297, maio-jun. 2013. ilus, tab
Article in Portuguese | LILACS | ID: lil-675682

ABSTRACT

Estudos recentes demonstram que a formação de miringoesclerose pode ser reduzida pela aplicação de enzimas e elementos antioxidantes. OBJETIVO: Investigar a eficácia da coenzima Q10 na prevenção de miringoesclerose experimentalmente induzida. MÉTODO: Quarenta e oito ratas Wistar albinas saudáveis sofreram miringotomia e foram divididas aleatoriamente em quatro grupos. O Grupo A não recebeu tratamento algum; o Grupo B recebeu coenzima Q10 por via oral; o Grupo C foi tratado com soro fisiológico tópico; e o Grupo D recebeu coenzima Q10 tópica. No 15º dia de tratamento, as membranas timpânicas foram examinadas por otomicroscopia. As lesões miringoescleróticas foram documentadas de forma semiquantitativa por meio de uma escala de quatro pontos. Após a coleta, as membranas timpânicas foram avaliadas por histopatologia. RESULTADOS: No grupo D (coenzima Q10 tópica) foi observada a ocorrência de otite nos primeiros quatro dias do estudo, o que levou à sua exclusão do estudo. O exame de otomicroscopia não revelou diferenças significativas entre grupos em termos de formação de miringoesclerose (p = 0,241). Diferenças estatisticamente significativas foram observada quando os exames histopatológicos do grupo A foram comparados aos dos grupos B e C (p = 0,004; p < 0,001, respectivamente). Não houve diferença significativa entre os grupos B e C (p = 0,160). CONCLUSÃO: A administração oral de coenzima Q10 não reduziu a formação de miringoesclerose nos ratos submetidos à miringotomia.


Recent studies have shown that the formation of myringosclerosis could be reduced by the application of antioxidant enzymes and elements. OBJECTIVE: The aim of this study was to investigate the effectiveness of coenzyme Q10 on the prevention of experimentally induced myringosclerosis. METHOD: Forty-eight healthy female wistar albino rats were bilaterally myringotomized and divided into four groups randomly. Group A received no treatment, group B was administered oral coenzyme Q10. Group C was treated with topical saline solution, group D received topically coenzyme Q10. On the 15th day of treatment, tympanic membranes were examined by otomicroscopy. Myringosclerotic lesions were documented semiquantitatively by using 4-point scale. After harvesting tympanic membranes were evaluated histopathologically. RESULTS: In group D (topical coenzyme Q10), we observed otitis within the first four days of the study and this group was excluded from the study. Regarding otomicroscopic examinations, there were no significant differences among groups in myringosclerosis formation (p = 0.241). When group A (non treatment) compared to groups B and C regarding histopathologic examination, the results demonstrated statistical significant differences (p = 0.004; p < 0.001), respectively. There was no statisticaly significant difference between groups B and C (p = 0.160). CONCLUSION: Oral administration of coenzyme Q10 did not reduce myringosclerosis formation in myringotomized rats.


Subject(s)
Animals , Female , Rats , Myringosclerosis/prevention & control , Ubiquinone/analogs & derivatives , Vitamins/therapeutic use , Disease Models, Animal , Myringoplasty , Myringosclerosis/pathology , Random Allocation , Rats, Wistar , Ubiquinone/therapeutic use
4.
Int. j. morphol ; 29(3): 876-884, Sept. 2011. ilus
Article in English | LILACS | ID: lil-608674

ABSTRACT

Dysferlinopathy is a form of muscular dystrophy affecting muscles of the shoulder and pelvic girdles, resulting from inheritance of a mutated dysferlin gene. The encoded dysferlin protein is proposed to be involved in sarcolemmal vesicle fusion with a disrupted plasma membrane; however, with defective protein function these vesicles accumulate beneath the disruption site but are unable to fuse with it and reseal the membrane, thus rendering the membrane repair mechanism defective. The SJL/J mouse model presents with characteristics much like the commonest human condition. Immune modulators have long been under study in the maintenance of muscle health in muscular dystrophies. Such supplementary treatment would ideally suppress inflammation, preventing the immune response toward degenerating muscle from causing additional muscle fiber death, and thus provide a mechanism by which to prolong the life of muscle fibers with inherently defective healing apparatus. For this purpose the anti-inflammatory supplement resveratrol and the membrane-protective supplement coenzyme Q10 were administered separately and in combination to experimental animals to determine their effectiveness in possible therapy of dysferlinopathy. The findings of this study report that low doses of resveratrol and coenzyme Q10 supplementation in exclusivity were unable to afford much protection to muscle fibers at the tissue level. High doses of coenzyme Q10 proved more effective in reducing attenuating inflammation; and combination treatment with resveratrol and coenzyme Q10 provided not only the membrane-protective effects of coenzyme Q10, but also the anti-inflammatory effects of resveratrol which failed to materialize at sufficient levels in exclusive administration.


Disferlinopatía es una forma de distrofia muscular que afecta a los músculos de los hombros y cintura pélvica, resultado de la herencia y mutación del gen de la distrofina. Sugerimos que la proteína codificada distrofina que integra la estructura sarcolemal con una membrana plasmática interrumpida, que al presentar una proteína defectuosa, las estructuras se acumulan debajo del sitio de alteración sin lograr fundirse con éste y cerrar la membrana afectando el mecanismo de reparación. El modelo de ratón SJL / J se presenta con características muy similares a una condición humana común. Los inmunomoduladores han sido objeto de estudio en el mantenimiento de la salud muscular en las distrofias musculares. Este tipo de tratamiento suplementario puede ser ideal para suprimir la inflamación, en la prevención de la respuesta inmune en la degeneración muscular causando la muerte adicional de fibra muscular, y al mismo tiempo proporcionar, un mecanismo con el cual prolongar la vida útil de aquellas fibras musculares con el aparato de sanación comprometido. Para ello, el Resveratrol suplemento anti-inflamatorio y el suplemento protector de membrana coenzima Q10 se administró por separado y en combinación en los animales de laboratorio para determinar su efectividad en el tratamiento de posible disferlinopatía. Los resultados de este estudio indican que el Resveratrol en menor dosis y la coenzima Q 10 administrados como suplementos de manera exclusiva, no demostraron efectos de protección de las fibras musculares a nivel del tejido. Una alta dosis de coenzima Q10 demostró ser más efectiva en la reducción de la inflamación; adicionalmente, el tratamiento combinado de Resveratrol y coenzima Q10 proporcionó efectos protectores de membrana, además de los efectos anti-inflamatorios del Resveratrol cuyo nivel no alcanzó la efectividad suficiente al ser administrado en forma exclusiva.


Subject(s)
Rats , Muscular Dystrophies, Limb-Girdle/drug therapy , Muscular Dystrophies, Limb-Girdle/therapy , Sarcolemma , Sarcolemma/immunology , Stilbenes/administration & dosage , Stilbenes/therapeutic use , Rats/growth & development , Rats/injuries , Ubiquinone/immunology , Ubiquinone/therapeutic use
5.
Rev. chil. dermatol ; 25(1): 8-20, 2009.
Article in Spanish | LILACS | ID: lil-525460

ABSTRACT

Nuestra piel está constantemente expuesta al estrés oxidativo endógeno y exógeno, el cual juega un papel fundamental tanto en el envejecimiento intrínseco como extrínseco. El estrés oxidativo se debe a la producción de especies reactivas de oxígeno, también conocidas como radicales libres. Las estructuras vitales que se ven afectadas por este proceso son el ADN, elementos del citoesqueleto, proteínas celulares y membranas celulares. El cuerpo posee mecanismos de defensa contra los radicales libres, denominados antioxidantes, los cuales son capaces de reducirlos y neutralizarlos. Sin embargo, como parte natural del proceso de envejecimiento, no sólo la producción de especies reactivas de oxígeno aumenta, sino que los mecanismos endógenos de defensa disminuyen, resultando en un desbalance con predominio de radicales libres no neutralizados que dañan las estructuras del organismo. Aunque el cuerpo posee antioxidantes endógenos y ciertos alimentos son ricos en antioxidantes, muchos creen que niveles más altos de estas sustancias pueden obtenerse con suplementos alimentarios. En consecuencia, ha llegado a ser muy popular el uso de antioxidantes en suplementos orales o en forma tópica, los cuales podrían potencialmente aminorar los efectos adversos de las especies reactivas de oxígeno. En esta revisión se analizan los antioxidantes más conocidos que se encuentran incorporados en los productos cosméticos o que son administrados por vía oral en los pacientes interesados en la cosmética personal.


Our skin is constantly exposed to endogenous and exogenous oxidative stress, which plays a pivotal role in intrinsic and extrinsic aging. Oxidative stress is delivered by the creation of reactive oxygen species also known as free radicals. Vital structures that can be adversely affected by this process are DNA, cytoskeletal elements, cellular proteins, and cellular membranes. The body possesses defense mechanisms against free radicals, which are called antioxidants, and are able to reduce and neutralize them. However, as part of the natural aging process, not only does the production of reactive oxygen species increase, but our endogenous defense mechanisms decrease resulting in an imbalance and increased number of unchecked free radicals damaging vital structures of the body. Although the body possesses endogenous antioxidants and certain foods are rich in antioxidants, many believe that higher levels can be achieved by supplementation. Consequently, the use of antioxidants as oral supplements or topical formulation should be able to lessen the harmful adverse effects induced by reactive oxygen species and has thus become popular. This review discusses the most popular types of antioxidants found in cosmetic products or taken orally by cosmetic patients.


Subject(s)
Humans , Antioxidants/therapeutic use , Skin Aging , Ascorbic Acid/therapeutic use , Coffee/chemistry , Carotenoids/therapeutic use , Curcumin/therapeutic use , Stilbenes/therapeutic use , Plant Extracts/therapeutic use , Polypodium/chemistry , Silymarin/therapeutic use , Tea , Ubiquinone/analogs & derivatives , Ubiquinone/therapeutic use , Vitamin E/therapeutic use
6.
Arq. bras. endocrinol. metab ; 52(8): 1345-1349, Nov. 2008. ilus
Article in English | LILACS | ID: lil-503303

ABSTRACT

Maternally inherited diabetes and deafness (MIDD) has been related to an A to G transition in the mitochondrial tRNA Leu (UUR) gene at the base pair 3243. This subtype of diabetes is characterized by maternal transmission, young age at onset and bilateral hearing impairment. Besides diabetes and deafness, the main diagnostic features, a wide range of multisystemic symptoms may be associated with the A3243G mutation. Organs that are most metabolically active, such as muscles, myocardium, retina, cochlea, kidney and brain are frequently affected. Gastrointestinal tract symptoms are also common in patients with mitochondrial disease and constipation and diarrhea are the most frequent manifestations. However, there are few prior reports of intestinal pseudo obstruction in MIDD patients. Here we report the case of a patient with MIDD associated with the mtDNA A3243G mutation who developed chronic intestinal pseudo obstruction, and the introduction of Coenzyme Q10 as adjunctive therapy led to a solution of the pseudo obstruction.


Diabetes mitocondrial ou diabetes e surdez de herança maternal (MIDD, acrônimo de maternally inherited diabetes and deafness) é freqüentemente associado à mutação mitocondrial A3243G. Esse subtipo de diabetes é caracterizado por transmissão materna, disacusia neuro-sensorial bilateral e idade precoce de aparecimento. Além do diabetes e da surdez, principais características diagnósticas, outros sintomas em diferentes órgãos podem também associar-se à mutação A3243G. Os órgãos que são metabolicamente mais ativos, tais como músculos, miocárdio, retina, cóclea, rim e cérebro, são freqüentemente afetados. Sintomas do trato gastrintestinal também são comuns em pacientes com doença mitocondrial, sendo diarréia e obstipação as manifestações mais freqüentes. Entretanto, há poucos relatos de pseudo-obstrução intestinal em portadores de diabetes mitocondrial. Este relato descreve o caso de uma paciente com diabetes mitocondrial que apresentou pseudo-obstrução intestinal e que com a introdução de coenzima Q10, como terapia adjunta, teve resolução o quadro.


Subject(s)
Female , Humans , Middle Aged , Diabetes Complications , Diabetes Mellitus , Deafness/complications , Intestinal Pseudo-Obstruction , Ubiquinone/analogs & derivatives , Vitamins/therapeutic use , DNA, Mitochondrial/genetics , Deafness/genetics , Diabetes Mellitus/genetics , Intestinal Pseudo-Obstruction/drug therapy , Intestinal Pseudo-Obstruction/genetics , Pedigree , Point Mutation/genetics , Ubiquinone/therapeutic use
7.
Rev. chil. neuro-psiquiatr ; 42(1): 49-52, ene. 2004.
Article in Spanish | LILACS | ID: lil-363586

ABSTRACT

With the current limitations on treating Parkinsonãs disease, neuroprotection should be looked at as a possible way of slowing the varying processes involved in the onset of the disease. A review was made of the work of NINDS experts, who evaluated 59 drugs resulting from their Medline and Pub Med search. Twelve drugs, those considered the most promising, were included in the final analysis. We look at such substances as caffeine, coenzyme q10, estrogens, minocycline, nicotine, rasagiline-selegiline, and ropinirole-pramipexole. These agents acted dissimilarly, but favorably, on some of the diseaseãs processes or on its underlying pathogenesis, although the mechanisms involved and the duration of the beneficial effects were not clear. The challenge is to overcome the difficulties that make the results of the few current studies uncertain, using new methods, such as transgenic models, to maintain hope for effective future treatments.


Subject(s)
Humans , Antiparkinson Agents/administration & dosage , Antiparkinson Agents/therapeutic use , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/therapeutic use , Parkinson Disease/therapy , Caffeine/therapeutic use , Estrogens/therapeutic use , Minocycline/therapeutic use , Nicotine/therapeutic use , Selegiline/therapeutic use , Ubiquinone/therapeutic use
9.
Yonsei Medical Journal ; : 676-679, 2000.
Article in English | WPRIM | ID: wpr-202103

ABSTRACT

Coenzyme Q therapy has been used to support metabolic derangements in patients with mitochondrial encephalomyopathies. Biochemical analysis of the living human brain can be performed by magnetic resonance spectroscopy (MRS). We report upon a KSS patient who was serially imaged with localized proton MRS to monitor the efficacy of CoQ treatment. A 17-year-old girl with KSS was serially imaged with localized proton MRS performed on a GE 1.5 T SIGNA MRI/MRS system. The elevated lactate contents of lesions decreased after one month of CoQ therapy but were re-elevated 10 months after treatment. We conclude that MRS presents us with a powerful tool for monitoring the effects of therapeutic trials in mitochondrial encephalomyopathies.


Subject(s)
Female , Humans , Adolescent , Brain/metabolism , Brain/drug effects , Kearns-Sayre Syndrome/metabolism , Kearns-Sayre Syndrome/drug therapy , Kearns-Sayre Syndrome/diagnosis , Lactic Acid/metabolism , Magnetic Resonance Spectroscopy , Pyruvic Acid/metabolism , Treatment Outcome , Ubiquinone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL